Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
Status:
Open
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) – A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study
NCT#05136196
S2101 will temporarily close to accrual on June 7, 2023, effective at 12:00pm Pacific Time.
